《慢性乙肝防治指南》(2010年版)参考文献

 

[1] 中华医学会肝病学分会、感染病学分会．慢性乙型肝炎防治指南[J]．中华肝脏病杂志，2005，13（12）：881-891．上海华山医院感染病科尹有宽 [2] Seeger C, Mason WS. Hepatitis B virus biology[J]. Microbiol Mol Biol Rev, 2000, 64(1):51-68. [3] Scaglioni PP, Melegari M, Wands JR. Biologic properties of hepatitis B viral genomes with mutations in the precore	promoter and precore open reading frame[J]. Virology, 1997, 233(2):374-381. [4] Tran TT, Trinh TN, Abe K. New complex recombinant genotype of hepatitis B virus identified in Vietnam[J]. J Virol, 2008, 82(11):5657-5663. [5] Olinger CM, Jutavijittum P, Hubschen JM, et al. Possible new
hepatitis B virus genotype, southeast Asia[J]. Emerg Infect Dis, 2008, 14(11):1777-1780. [6] Chu CJ, Hussain M, Lok AS. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C[J]. Gastroenterology, 2002, 122(7):1756-1762. [7] Chu CM, Liaw YF. Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B:a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline[J]. J Hepatol, 2005, 43(3):411-417. [8] Yu MW, Yeh SH, Chen PJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma:a prospective study in men[J]. J Natl Cancer Inst, 2005, 97(4):265-572. [9] Zhang HW, Yin JH, Li YT, et al. Risk factors for acute hepatitis B and its progression to chronic hepatitis in Shanghai, China[J]. Gut, 2008, 57(12):1713-1720. [10] Hou J, Schilling R, Janssen HL, et al. Genetic characteristics of hepatitis B virus genotypes as a factor for interferon-induced HBeAg clearance[J]. J Med Virol, 2007, 79(8):1055-1063. [11] Jardi R, Rodriguez-Frias F, Schaper M, et al. Analysis of hepatitis B genotype changes in chronic hepatitis B infection:influence of antiviral therapy[J]. J Hepatol, 2008, 49(5):695-701. [12] Liu CJ, Kao JH. Genetic variability of hepatitis B virus and response to antiviral therapy[J]. Antivir Ther, 2008, 13(5):613-624. [13] Ganem D, Prince AM. Hepatitis B virus infection--natural history and clinical consequences[J]. N Engl J Med, 2004, 350(11):1118-1129. [14] World Health Organization. Hepatitis B（[EB/OL]）（. Revised August 2008）. [2010-12-9]. http://www.who.int/mediacentre/ factsheets/fs204/en/. [15] Liang X, Bi S, Yang W, et al. Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination[J]. Vaccine, 2009, 27(47):6550-6557. [16] Liang X, Bi S, Yang W, et al. Evaluation of the impact of hepatitis B vaccination among children born during 1992-2005 in China[J]. J Infect Dis, 2009, 200(1):39-47. [17] Lu FM, Zhuang H. Management of hepatitis B in China[J]. Chin Med J （Engl）, 2009, 122(1):3-4. [18] Mast EE, Margolis HS, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States:recommendations of the Advisory Committee on Immunization Practices （ACIP） part 1:immunization of infants, children, and adolescents[J]. MMWR Recomm Rep, 2005, 54（RR-16）:1-31. [19] World Health Organization. Hepatitis B[EB/OL]. [2010- 12-9]. http://www.who.int/csr/disease/hepatitis/HepatitisB_	whocdscsrlyo2002_2.pdf. [20] Lai CL, Ratziu V, Yuen MF, et al. Viral hepatitis B[J]. Lancet, 2003, 362(9401):2089-2094. [21] Liaw YF. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment[J]. Liver Int, 2009, 29(Suppl 1):100-107. [22] Hui CK, Leung N, Yuen ST, et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immunetolerant phase[J]. Hepatology, 2007, 46(2):395-401. [23] McMahon BJ. The natural history of chronic hepatitis B virus infection[J]. Hepatology, 2009, 49（5 Suppl）:S45-S55. [24] Liaw YF. Hepatitis flares and hepatitis B e antigen seroconversion:implication in anti-hepatitis B virus therapy[J]. J Gastroenterol Hepatol, 2003, 18(3):246-252. [25] Chu CM, Hung SJ, Lin J, et al. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels[J]. Am J Med, 2004, 116(12):829-834. [26] Fattovich G, Brollo L, Alberti A, et al. Long-term follow-up of anti-HBe-positive chronic active hepatitis B[J]. Hepatology, 1988, 8(6):1651-1654. [27] Brunetto MR, Oliveri F, Rocca G, et al. Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen[J]. Hepatology, 1989, 10(2):198-202. [28] Di MV, Lo IO, Camma C, et al. The long-term course of chronic hepatitis B[J]. Hepatology, 1999, 30(1):257-264. [29] Chu CM, Liaw YF. Hepatitis B virus-related cirrhosis:natural history and treatment[J]. Semin Liver Dis, 2006, 26(2):142-152. [30] Chen YC, Chu CM, Yeh CT, et al. Natural course following the onset of cirrhosis in patients with chronic hepatitis B:a longterm follow-up study[J]. Hepatol Int, 2007, 1(1):267-273. [31] Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B[J]. Hepatology, 2002, 35(6):1522-1527. [32] Chou YC, Yu MW, Wu CF, et al. Temporal relationship between hepatitis B virus enhancer II/basal core promoter sequence variation and risk of hepatocellular carcinoma[J]. Gut, 2008, 57(1):91-97. [33] Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level[J]. JAMA, 2006, 295(1):65-73. [34] Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma[J]. N Engl J Med, 2002, 347(3):168-174. [35] Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load[J]. Gastroenterology, 2006, 130(3):678-686. [36] Tai DI, Chen CH, Chang TT, et al. Eight-year nationwide
survival analysis in relatives of patients with hepatocellular carcinoma:role of viral infection[J]. J Gastroenterol Hepatol, 2002, 17(6):682-689. [37] 中国疾病预防控制中心．乙型肝炎疫苗儿童计划免疫技术 管理规程（试行）[J]．2002． [38] 夏国良，龚健，王继杰，等．重组乙型肝炎疫苗阻断乙型 肝炎病毒母婴传播方案的保护效果评价[J]．中华流行病学 杂志，2003，24（5）：362-365． [39] 邢玉兰，龚晓红，周绍莲，等．阻断围产期母婴传播最佳 免疫方案的研究[J]．中华实验和临床病毒学杂志，1990， 4：485-488． [40] Center for Disease Prevention and Control. Breastfeeding[EB/ OL]. [2010-12-8]. http://www.cdc.gov/breastfeeding/disease/ hepatitis.htm. [41] World Health Organization. Hepatitis B and breastfeeding[EB/ OL]. [2010-12-8]. http://www.who.int/child_adolescent_ health/documents/ pdfs/hepatitis_b_and_ breastfeeding.pdf. [42] Zanetti AR, Mariano A, Romano L, et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster:an Italian multicentre study[J]. Lancet, 2005, 366(9494):1379-1384. [43] John TJ, Cooksley G. Hepatitis B vaccine boosters:is there a clinical need in high endemicity populations[J]. J Gastroenterol Hepatol, 2005, 20(1):5-10. [44] U.S. Public Health Service. Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis[J]. MMWR Recomm Rep, 2001,50 （RR-11）:1-52. [45] 中华医学会传染病与寄生虫病学分会、肝病学分会．病毒 性肝炎防治方案[J]．中华肝脏病杂志，2000，8（6）： 324-329． [46] Pawlotsky JM, Dusheiko G, Hatzakis A, et al. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice:recommendations for a standardized approach[J]. Gastroenterology, 2008, 134(2):405-415. [47] Shaheen AA, Wan AF, Myers RP. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis:a systematic review of diagnostic test accuracy[J]. Am J Gastroenterol, 2007, 102(11):2589-2600. [48] Scot t DR, Levy MT. Live r t r ans i ent e l a s togr aphy （Fibroscan）:a place in the management algorithms of chronic viral hepatitis[J]. Antivir Ther, 2010, 15(1):1-11. [49] Lok AS, McMahon BJ. Chronic hepatitis B:update 2009[J]. Hepatology, 2009, 50:661-662. [50] Lin SM, Yu ML, Lee CM, et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma[J]. J Hepatol, 2007, 46(1):45-52. [51] Manesis EK, Hadziyannis SJ. Interferon alpha treatment and	retreatment of hepatitis B e antigen-negative chronic hepatitis B[J]. Gastroenterology, 2001, 121(1):101-109. [52] Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B[J]. N Engl J Med, 2005, 352(26):2682-2695. [53] Piratvisuth T, Lau G, Chao YC, et al. Sustained response to peginterferon alfa-2a （40 kD） with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B[J]. Hepatol Int, 2008, 2(1):102-110. [54] Chan HL, Leung NW, Hui AY, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B:comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone[J]. Ann Intern Med, 2005, 142(4):240-250. [55] Flink HJ, van ZM, Hansen BE, et al. Treatment with Peginterferon alpha-2b for HBeAg-positive chronic hepatitis B:HBsAg loss is associated with HBV genotype[J]. Am J Gastroenterol, 2006, 101(2):297-303. [56] Buster EH, Flink HJ, Cakaloglu Y, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAgpositive patients treated with peginterferon alpha-2b[J]. Gastroenterology, 2008, 135(2):459-567. [57] Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B[J]. N Engl J Med, 2004, 351:1206-1217 [58] Marcellin P, Bonino F, Lau GK, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a[J]. Gastroenterology, 2009, 136(7):2169-2179. [59] Lok AS, McMahon BJ. Chronic hepatitis B[J]. Hepatology, 2007, 45(2):507-539. [60] Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States:an update[J]. Clin Gastroenterol Hepatol, 2006, 4(8):936-962. [61] Fried MW, Piratvisuth T, Lau GK, et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B[J]. Hepatology, 2008, 47(2):428-434. [62] Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop:a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients[J]. Hepatology, 2009, 49(4):1151-1157. [63] Brunetto MR, Moriconi F, Bonino F, et al. Hepatitis B virus surface antigen levels:a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B[J]. Hepatology, 2009, 49(4):1141-1150. [64] Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B[J]. Gastroenterology,
2003, 125(6):1714-1722. [65] Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group[J]. N Engl J Med, 1998, 339(2):61-68. [66] Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group[J]. Gastroenterology, 2000, 119(1):172-180. [67] Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States[J]. N Engl J Med, 1999, 341(17):1256-1263. [68] Chien RN, Liaw YF, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group[J]. Hepatology, 1999, 30(3):770-774. [69] Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological out come dur ing long- t e rm l amivudine the r apy[ J ] . Gastroenterology, 2003, 124(1):105-117. [70] Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease[J]. N Engl J Med, 2004, 351(15):1521-1531. [71] Villeneuve JP, Condreay LD, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B[J]. Hepatology, 2000, 31(1):207-210. [72] Perrillo RP, Wright T, Rakela J, et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B[J]. Hepatology, 2001, 33(2):424-432. [73] Hann HW, Fontana RJ, Wright T, et al. A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis[J]. Liver Transpl, 2003, 9(1):49-56. [74] Jonas MM, Mizerski J, Badia IB, et al. Clinical trial of lamivudine in children with chronic hepatitis B[J]. N Engl J Med, 2002, 346(22):1706- 1713. [75] Figlerowicz M, Kowala-Piaskowska A, Filipowicz M, et al. Efficacy of lamivudine in the treatment of children with chronic hepatitis B[J]. Hepatol Res, 2005, 31(4):217-222. [76] 姚光弼，崔振宇，姚集鲁，等．国产拉米夫定治疗2200 例慢性乙型肝炎的Ⅳ期临床试验[J]．中华肝脏病杂志， 2003，11（2）：103-108． [77] 姚光弼，王宝恩，崔振宇，等．拉米夫定治疗慢性乙型肝炎 三年疗效观察[J]．中华内科杂志，2003，42（6）：382-387． [78] 曾民德，茅益民，姚光弼，等．阿德福韦酯治疗HBeAg阳性 的中国慢性乙型病毒性肝炎患者52周的多中心临床研究[J]． 中华传染病杂志，2005，23（6）：387-394． [79] Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis	B[J]. N Engl J Med, 2003, 348(9):808-816. [80] Marcellin P, Chang TT, Lim SG, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B[J]. Hepatology, 2008, 48(3):750-758. [81] Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Longterm therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years[J]. Gastroenterology, 2006, 131(6):1743-1751. [82] Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B[J]. N Engl J Med, 2005, 352(26):2673-2681. [83] Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B[J]. N Engl J Med, 2003, 348(9):800-807. [84] Lampertico P, Vigano M, Manenti E, et al. Low resistance to adefovir combined with lamivudine:a 3-year study of 145 lamivudine-resistant hepatitis B patients[J]. Gastroenterology, 2007, 133(5):1445-1451. [85] Rapti I, Dimou E, Mitsoula P, et al. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B[J]. Hepatology, 2007, 45(2):307-313. [86] Lampertico P, Vigano M, Manenti E, et al. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine[J]. Hepatology, 2005, 42(6):1414-1419. [87] Peters MG, Hann HH, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudineresistant chronic hepatitis B[J]. Gastroenterology, 2004, 126(1):91-101. [88] Perrillo R, Hann HW, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus[J]. Gastroenterology, 2004, 126(1):81-90. [89] Marzano A, Lampertico P, Mazzaferro V, et al. Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants[J]. Liver Transpl, 2005, 11(5):532-538. [90] 张雅敏，朱志军，郑虹，等．阿德福韦在预防肝移植后乙 肝复发中的应用[J]．中华肝胆外科杂志，2006，12（5）： 313-315． [91] Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B[J]. N Engl J Med, 2006, 354(10):1001-1010. [92] Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B[J]. N Engl J Med, 2006, 354(10):1011-1020. [93] Gish RG, Lok AS, Chang TT, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis
B[J]. Gastroenterology, 2007, 133(5):1437-1444. [94] Yokosuka O, Takaguchi K, Fujioka S, et al. Long-term use of entecavir in nucleoside-naive Japanese patients with chronic hepatitis B infection[J]. J Hepatol, 2010, 52(6):791-799. [95] Sherman M, Yurdaydin C, Sollano J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B[J]. Gastroenterology, 2006, 130(7):2039-2049. [96] 姚光弼，计焱焱，任红，等．恩替卡韦治疗拉米夫定失效 慢性乙型肝炎一年的疗效[J]．中华传染病杂志，2006，24 （6）：385-389． [97] 姚光弼，朱玫，王宇明，等．恩替卡韦与拉米夫定治疗慢 性乙型肝炎随机、双盲、双模拟对照研究[J]．中华内科杂 志，2006，45（11）：891-895． [98] Liaw YF, Gane E, Leung N, et al. 2-Year GLOBE trial results:telbivudine Is superior to lamivudine in patients with chronic hepatitis B[J]. Gastroenterology, 2009, 136(2):486-495. [99] Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B[J]. N Engl J Med, 2007, 357(25):2576-2588. [100] Hou J, Yin YK, Xu D, et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B:Results at 1 year of a randomized, double-blind trial[J]. Hepatology, 2008, 47(2):447-454. [101] Zeuzem S, Gane E, Liaw YF, et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B[J]. J Hepatol, 2009, 51(1):11-20. [102] 贾继东，侯金林，尹有宽，等．替比夫定或拉米夫定抗乙 型肝炎病毒的疗效预测探讨[J]．中华肝脏病杂志，2007， 15（5）：342-345． [103] Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B[J]. N Engl J Med, 2008, 359(23):2442-2455. [104] Heathcote EJ, Marcellin P, Buti M, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B[J]. Gastroenterology, 2011, 140(1):132-143.	[105] Yuen MF, Fong DY, Wong DK, et al. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response[J]. Hepatology, 2007, 46(6):1695-1703. [106] Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop:roadmap for management of patients receiving oral therapy for chronic hepatitis B[J]. Clin Gastroenterol Hepatol, 2007, 5(8):890-897. [107] Chan HL, Tang JL, Tam W, et al. The efficacy of thymosin in the treatment of chronic hepatitis B virus infection:a metaanalysis[ J]. Aliment Pharmacol Ther, 2001, 15(5):1899-1905. [108] Chien RN, Liaw YF, Chen TC, et al. Efficacy of thymosin alpha1 in patients with chronic hepatitis B:a randomized, controlled trial[J]. Hepatology, 1998, 27(5):1383-1387. [109] Hui CK, Cheung WW, Zhang HY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy[J]. Gastroenterology, 2006, 131(1):59-68. [110] 中华医学会感染病学分会肝衰竭与人工肝学组、中华医学会 肝病学分会重型肝病与人工肝学组．肝衰竭诊疗指南[J]．中 华肝脏病杂志，2006，14（9）：643-646． [111] Hung IF, Poon RT, Lai CL, et al. Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection[J]. Am J Gastroenterol, 2008, 103（7）:1663-1673. [112] Koda M, Nagahara T, Matono T, et al. Nucleotide analogs for patients with HBV-related hepatocellular carcinoma increase the survival rate through improved liver function[J]. Intern Med, 2009, 48（1）:11-17. [113] Zhang FK, Liu DG, Jia JD. Antiviral therapy for hepatitis B in special populations[J]. Antivir Ther, 2010, 15(8):1067-1075. [114] Sokal EM, Kelly D, Wirth S, et al. The pharmacokinetics and safety of adefovir dipivoxil in children and adolescents with chronic hepatitis B virus infection[J]. J Clin Pharmacol, 2008, 48（4）:512-517.